MG
TVRD

Michael Gelband’s Tvardi Therapeutics TVRD Stock Holding History

Michael Gelband’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,935
Closed -$1.05M – 2320
2023
Q1 		$1.05M Sell
5,935
-4,378
-42% -$1.47M 0.01% 1127
2022
Q4 		$3.99M Buy
10,313
+6,687
+184% +$2.54M 0.06% 412
2022
Q3 		$1.22M Buy
3,626
+105
+3% +$38K 0.02% 1026
2022
Q2 		$1.16M Buy
3,521
+2,100
+148% +$737K 0.01% 1013
2022
Q1 		$622K Buy
1,421
+638
+81% +$262K 0.01% 1407
2021
Q4 		$343K Buy
+783
New +$393K ﹤0.01% 1608
2021
Q3 		– Sell
-497
Closed -$255K – 2750
2021
Q2 		$255K Sell
497
-946
-66% -$599K ﹤0.01% 1836
2021
Q1 		$1.13M Buy
+1,443
New +$988K 0.02% 847
2020
Q4 		– Sell
-608
Closed -$278K – 2464
2020
Q3 		$278K Buy
608
+150
+33% +$87.1K 0.01% 1320
2020
Q2 		$282K Buy
+458
New +$253K 0.01% 1347
2020
Q1 		– Sell
-577
Closed -$334K – 1733
2019
Q4 		$334K Buy
+577
New +$405K 0.01% 1093

Other funds holding TVRD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's TVRD Position: Q2 2023 in Review

Michael Gelband sold out of Tvardi Therapeutics (TVRD) in Q2 2023, closing a stake of 5,935 shares — an estimated $1.05M sold.

Michael Gelband first reported a position in TVRD in Q4 2019 and held it in 11 quarters. The position peaked at $3.99M in Q4 2022. 137 funds tracked by Wall St. Rank hold TVRD as of Q2 2023.

  • Michael Gelband reported no remaining Tvardi Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Michael Gelband sold 5,935 Tvardi Therapeutics shares in Q2 2023, an estimated $1.05M.
  • Michael Gelband first reported a position in Tvardi Therapeutics in Q4 2019 and held it in 11 quarters.
  • Michael Gelband's Tvardi Therapeutics position peaked at $3.99M in Q4 2022.
  • 137 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2023.

Based on ExodusPoint Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.